New hope for transplant patients: drug targets stubborn immune attack

NCT ID NCT06343792

Recruiting now Disease control Sponsor: ReAlta Life Sciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called RLS-0071 in 66 hospitalized patients who have severe graft-versus-host disease (GVHD) after a stem cell transplant and did not improve with steroids. The drug is given for 7 to 14 days to see if it is safe and helps control the immune reaction. The goal is to find the right dose and measure how well patients respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RLS-0071
What this could lead to: If successful, this could offer a new treatment option for patients with severe graft-versus-host disease that does not respond to steroids.
What could go wrong: This is an early Phase 2 trial with only 66 participants, so results may not apply broadly. The drug may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEROID REFRACTORY GVHD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STEROID REFRACTORY GVHD

Contacts and locations

Locations

Site 1068
ACTIVE_NOT_RECRUITING

St Louis, Missouri, 63110, United States
Site 1091
ACTIVE_NOT_RECRUITING

Duarte, California, 91010, United States
Site 1100
ACTIVE_NOT_RECRUITING

Cincinnati, Ohio, 45229, United States
Site 1318
ACTIVE_NOT_RECRUITING

Atlanta, Georgia, 30041, United States
Site 1343
ACTIVE_NOT_RECRUITING

Los Angeles, California, 90095, United States
Site 1382
ACTIVE_NOT_RECRUITING

Columbus, Ohio, 43210, United States
Site 3101
RECRUITING

Seville, SE, 41013, Spain
Site 3101
RECRUITING

Seville, Spain
Site 3227
RECRUITING

Salamanca, Spain
Site 3242
RECRUITING

Freiburg im Breisgau, 79106, Germany
Site 3360
RECRUITING

Madrid, Spain